PRODUCTS & SERVICES
Group ACYW135 Meningococcal Polysaccharide Vaccine
The vaccine is a preparation of purified capsular polysaccharide antigens extracted from the cultures of Neisseria meningitidis group A, C, Y and W135 respectively and lyophilized after addition of an appropriate stabilizer. The final product looks like a white loose cake. It shall turn into a clear liquid after reconstitution.
Haemophilus Influenzae Type b Conjugate Vaccine
The vaccine is colourless transparent liquid with preservative, conjugated purified Haemophilus b capsular polysaccharide with the tetanus toxoid.
Haemophilus Influenza Type b Vaccine (XiFeiBei®)
The vaccine was made from the attenuated strain of HAV, inoculated in human diploid cells through culture, harvesting and purification of the extracted preparation, added with adequate stabilizer and through lyophilization. The vaccine is a loose substance with cheese colour and is transparent liquid after re-dissolution.
Mycobacterium Vaccae for Injection (Vaccae®)
Vaccae® is a sterile, white to pale yellow, preservative free lyophilized powder for deep intramuscular administration. Each vial of Vaccae® contains 0.5milligram heat-killed Mycobacterium vaccae mass (or counted as 22.5microgram total bacterial proteins), 1.25 milligram sucrose, 1.25milligram sodium glutamate,1.25milligram sodium chloride, 0.725milligram NaH2PO3 and 3.05milligram Na2HPO3. When dissolved with water for injection, the reconstituted solution should be clear and transparent, at a pH approximately 7.0, and has no insoluble substance visible to naked eyes.
Meningococcal Groups A and C and Haemophilus b Conjugate Vaccine
This product is made using purified polysaccharide of Neisseria meningitidis group A and C, polysaccharide of Haemophilus influenza type b, after covalent binding and purification with tetanus toxoid respectively, adding aluminium hydroxide adjuvant for absorption. It is manufactured as milky-white suspension, which should not contain insoluble massive substance after shaking.
Meningococcal Group A and C Conjugate Vaccine
This vaccine is prepared by covalently binding the purified capsular polysaccharide from Neisseria meningitides group A and C to tetanus toxoid protein, purifying and adsorbed after addition of aluminum hydroxide. This product is milky white liquid suspension and should not contain clumps not dispersed on shaking.